KRd for 8 cycles of induction and consolidation therapy in patients with MM was highly effective but resulted in some cardiovascular adverse events.
Weekly carfilzomib with pomalidomide and low-dose dexamethasone appears effective with better tolerability in relapsed/refractory MM.
This open-label, multicenter, dose-finding phase Ib trial suggests that subcutaneous daratumumab plus rHuPH20 is safe and effective in patients with relapsed/refractory MM.
Response-adapted use of sequential IMiD- and PI-based induction therapy improves response depth and PFS in newly diagnosed multiple myeloma.
Addition of daratumumab to either Rd or Vd significantly increased MRD-negative responses even in high-risk patients with relapsed/refractory multiple myeloma.
Venetoclax was safe and tolerable in heavily pretreated patients with myeloma with an ORR of 40% in patients with t(11;14) translocation.
Combination treatment with pembrolizumab plus pomalidomide/dexamethasone showed an ORR of 65% in relapsed/refractory MM.
First-in-class XPO1 inhibitor selinexor, in combination with low-dose dexamethasone, shows encouraging activity in heavily pretreated patients with MM refractory to multiple immunomodulatory agents, proteasome inhibitors, and anti-CD-38 monoclonal antibodies, according to the phase II STORM trial data.
Combination daratumumab/pomalidomide/dexamethasone produced deep responses and long PFS in patients with R/R MM, including those refractory to IMiDs and proteasome inhibitors.
In this Expert Analysis, Sagar Lonial, MD, and Shaji Kumar, MD, discuss the clinical applicability of new, key findings in multiple myeloma presented at Hematology 2016.
After current standard-of-care induction therapy for newly diagnosed MM, similar survival outcomes seen with single ASCT and maintenance lenalidomide with or without additional RVD consolidation or tandem ASCT even in patients with high-risk disease.
In this downloadable slideset, Shaji Kumar, MD, and Sagar Lonial, MD, highlight the key data presented at Hematology 2016.